The event will take place September 13-14 at the Fairmont Copley Square Hotel in Boston, MA. “The trend to globalization creates opportunities and challenges for clinical trial management. To be successful, we must focus on quality, ethics, fair market value, logistics and culture,” says Dr Barbara Skinn, Director of Collaborative Science Center of Excellence at Bristol-Myers Squibb.
Leadership
Led by Dr Skinn along with Dr Mitchell Katz, Executive Director Medical Research Operations at Purdue Pharma and Dr Aleksander Skuban, Director, Clinical R&D Emerging Markets at Merck.
Keynotes
Dr Debra S. Barker, Chief Scientific Officer, Emerging Markets, Novartis and Dr Christopher Gallen, CEO, SK Bio-Pharmaceuticals are delivering the keynote addresses. David R. Jones, Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), UK is a featured presenter speaking on How to Do Clinical Trials in Europe: Clarifying Confusion, Changes & Updates.
Regional Round Tables - Opening for Speakers!
As part of the conference, attendees will participate in region-specific round table discussions, including one-on-one question time with an industry expert in the following countries:
China • EU • Latin America • India • Russia/Ukraine • Canada Brazil • Eastern Europe • Australia • Korea
With the expansion of the round tables due to popular demand, there are three openings for either a pharma/biotech or CRO with solid clinical trial experience in one of the above countries to join the speaking faculty. To inquire, please email us.
Participating companies include: Novartis; BBK Worldwide; CSL Behring; Endo; Strategic Clinical Research Consulting, LLC; Baxter Healthcare Corporation; SK Bio- Pharmaceuticals; Millenium Pharmaceuticals; Momenta Pharmaceuticals; Medicines and Healthcare Products Regulatory Agency (MHRA), UK; Purdue Pharma LP; EnVivo Pharmaceuticals, Inc; Target Health; AMAG Pharmaceuticals; Merck Brazil; Merck Research Laboratories; Bristol-Myers Squibb; AAHRPP; Marken, Vertex and Zalicus.
For more information on the complete speaking faculty and agenda details, click here.
Registration
10% discount with code TEML. Register today, click here.
Questions: email us
Leadership
Led by Dr Skinn along with Dr Mitchell Katz, Executive Director Medical Research Operations at Purdue Pharma and Dr Aleksander Skuban, Director, Clinical R&D Emerging Markets at Merck.
Keynotes
Dr Debra S. Barker, Chief Scientific Officer, Emerging Markets, Novartis and Dr Christopher Gallen, CEO, SK Bio-Pharmaceuticals are delivering the keynote addresses. David R. Jones, Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), UK is a featured presenter speaking on How to Do Clinical Trials in Europe: Clarifying Confusion, Changes & Updates.
Regional Round Tables - Opening for Speakers!
As part of the conference, attendees will participate in region-specific round table discussions, including one-on-one question time with an industry expert in the following countries:
China • EU • Latin America • India • Russia/Ukraine • Canada Brazil • Eastern Europe • Australia • Korea
With the expansion of the round tables due to popular demand, there are three openings for either a pharma/biotech or CRO with solid clinical trial experience in one of the above countries to join the speaking faculty. To inquire, please email us.
Participating companies include: Novartis; BBK Worldwide; CSL Behring; Endo; Strategic Clinical Research Consulting, LLC; Baxter Healthcare Corporation; SK Bio- Pharmaceuticals; Millenium Pharmaceuticals; Momenta Pharmaceuticals; Medicines and Healthcare Products Regulatory Agency (MHRA), UK; Purdue Pharma LP; EnVivo Pharmaceuticals, Inc; Target Health; AMAG Pharmaceuticals; Merck Brazil; Merck Research Laboratories; Bristol-Myers Squibb; AAHRPP; Marken, Vertex and Zalicus.
For more information on the complete speaking faculty and agenda details, click here.
Registration
10% discount with code TEML. Register today, click here.
Questions: email us
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
